Eli Lilly drug shows 4-year relief for eczema patients, study finds

The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection

Merck strikes $6.7 billion deal to acquire terns, bolstering cancer pipeline

TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances

Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug

The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials

Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy

The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety

Avid Organics launches first commercial-scale bio-based glycolic acid at in-cosmetics Global

India’s largest glycolic acid manufacturer will unveil AviGa Bio HP70 on April 14, 2026

Aesthetic Revolution: Global study reveals patients demand personalised, long-term beauty plans

The company, part of pharma powerhouse AbbVie, will showcase the findings—and the next evolution of its AA Signature framework—at AMWC 2026 in Monaco,

Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare

KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval

Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU

These approvals represent a defining moment for people living with classical Hodgkin Lymphoma

Roche breaks lab barriers as FDA clears mass spec tests for wider use

The newly classified assays join Roche’s Ionify 25-Hydroxy Vitamin D total assay in a growing U.S. portfolio

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial